Most material SEC filings — September 15, 2026

SOBR Safe, Inc. received notice on 2026-09-14 of delisting or failure to satisfy continued listing rules. The company (market cap ~$3.5M) filed an 8-K on 2026-09-15 reporting Item 3.01 (delisting notice). No specific cure timeline, dollar amounts, or operational details are disclosed in this filing excerpt.

Flag Ship Acquisition Corp. (SPAC, ~$72M market cap) entered into a merger agreement dated September 15, 2026 with Bluechip Co. Holdings, a Cayman Islands company providing insurance-related customer acquisition, financial education, and AI-driven services through Hong Kong subsidiaries. The deal values Bluechip at $400 million in merger consideration (paid as 40 million Purchaser Ordinary Shares at $10/share). Closing contingent on SEC effectiveness, parent shareholder approval, and regulatory approvals; Outside Date is June 20, 2027.

XMax Inc. filed an 8-K on 2026-09-15 reporting Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard. The filing indicates a transfer of listing is pending. No specific dollar amounts, counterparties, or detailed remediation steps are disclosed in the available filing text.

GT Biopharma, Inc. (market cap ~$8.6M) issued 8,277.778 shares of Series M 10% Convertible Preferred Stock on September 14, 2026, at $1,000 stated value per share ($8.3M aggregate, $7.45M cash raised). Securities include conversion rights at $6.10/share into common stock, warrants exercisable at $6.10 for 5 years, and vesting warrants. Holders entitled to 10% annual dividends (12% after Sept 2027) and anti-dilution protection. Company granted up to $30M greenshoe rights. Registration of conversion shares required within 90 days or liquidated damages accrue.

In July 2026, Azio AI Corporation merged into Envirotech Vehicles, Inc. (now Azio AI Holdings). Azio AI shareholders received 2,460,351 shares of EVTV common stock (~$4.1M at $1.67/share) and 973,450 shares of Series A Preferred Stock (~$13.6M, convertible 100:1 to common upon stockholder approval). The merger valued total consideration at ~$21.7M. Azio AI had $666K assets, $4.5M liabilities (including $250K convertible notes), $3.8M accumulated deficit as of June 30, 2026.

Rocket Lab Corporation agreed to acquire all outstanding common stock of Iridium Communications Inc. pursuant to a merger agreement dated June 28, 2026. Lenders consented to this transaction (the "Amendment No. 4 Transactions") on September 15, 2026, waiving the change-of-control default that would otherwise occur. Following closing, Iridium will be owned by Rocket Lab USA, Inc., a subsidiary of RKLB Corp. The consent fee to lenders is 0.50% of outstanding Term Loans; consenting lenders also receive their pro-rata share of consent fees. The amendment became effective September 15, 2026, pending satisfaction of closing conditions including acquisition consummation and delivery of a downstream guaranty from RKLB USA.

Dream Finders Homes (market cap ~$478M) entered a subscription agreement dated September 14, 2026, to issue Series B Convertible Preferred Stock in two tranches: $225M at Closing (immediately) and $450M at Second Closing (contingent on Beazer merger completion). Total consideration: $675M gross ($657.2M net after 2.5% original issue discount). Counterparty: Kennedy Lewis Investment Management (KLIM) and/or its affiliates. Shares convertible into Class A Common Stock at stated price; investors receive board observer rights, registration rights, standstill provisions (18-month lock-up), and voting agreements. Merger Transaction is the Beazer Homes USA acquisition; Second Closing proceeds fund merger consideration.

RTB Digital (NASDAQ: RTB, market cap ~$8.5M) announced a "transformational" strategic partnership previously disclosed as involving a $10 million deposit. CEO James Heckman will host a shareholder call on September 17, 2026 at 11:00 a.m. ET to share transaction details, economics, and financial forecasts. No counterparty name, final deal terms, or transaction structure disclosed in this filing.

Launch Two Acquisition Corp. (NASDAQ: LPBB, market cap ~$239.7M) and NuCube Energy, Inc. jointly announced public filing of a Form S-4 registration statement with the SEC on September 11, 2026, advancing their proposed business combination originally announced June 25, 2026. The merger is subject to shareholder approval and customary closing conditions; no specific valuation, share count, or financial terms are disclosed in this press release.

A major US retailer (unnamed, but described as Global Fortune 50) has committed to a new LED lighting and IoT retrofit project estimated at $10–15M in revenue at additional locations. Orion expects to recognize a significant majority of this revenue in H2 FY2027 (ending March 31, 2027). In response, Orion raised full-year FY2027 revenue guidance from $95–97M to $100–102M, a $5–7M increase (5.3–7.4% upward revision).

Insider GL Part SPV II, LLC (SAFX) bought 6.9M shares (~$17.2M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.

HeartSciences (market cap ~$10.4M) announced a proposed business combination with Fortitude Mining Holdings, a Zcash-focused digital asset mining company, expected to close in Q4 2026. Fortitude invested approximately $1.0M in HeartSciences common stock in August 2026 without adjusting the merger exchange ratio. For fiscal Q1 2027 (ended July 31, 2026), HeartSciences reported zero meaningful revenue, a $3.2M net loss, and a $2.0M shareholders deficit; the company recorded a $0.3M inventory reserve against its MyoVista wavECG device and is de-prioritizing its FDA 510(k) submission in favor of its MyoVista Insights cloud platform, which has secured first US commercial agreements and selection at a major European reference center.

Change Agents Corporation filed Amendment No. 2 to Form S-1 on September 15, 2026, registering 5,360,797 common shares for sale by existing shareholders. The shares include: 5M put shares from Hudson Global Ventures LLC at $2.00/share (via Equity Purchase Agreement amended three times through September 9, 2026); 46,297 warrant shares from Hudson at $0.20/share exercise price; smaller grants to Agile Capital Funding LLC (28K shares total), Vision Capital NY Inc. (15K), Dune Equity Holdings LLC (15K), One-Eyed Jack Enterprises LLC (22.5K); and pre-funded warrant shares issued to C/M Capital Master Fund LP (122.7K), WVP Emerging Manager Onshore Fund LLC (27.3K), Dune Equity Holdings LLC (50K), and FirstFire Global Opportunities Fund LLC (34K) between August 14 and September 8, 2026.

Director Wilks Matthew (FTK) bought 1.3M shares (~$34.3M) on the open market (47% of holdings). Open-market insider purchase — historically a bullish signal.

Through September 14, 2026, FG Nexus repurchased approximately 4.0 million common shares for $48.0 million aggregate (46% of pre-program outstanding), leaving 4,707,615 shares outstanding. Additionally, the company repurchased ~275,000 preferred shares for $6.9 million (31% of pre-program preferred outstanding), leaving 619,357 preferred shares outstanding. Both repurchase programs remain authorized and open-ended; timing and amount of future repurchases depend on market conditions, liquidity, and capital-allocation priorities.

Lindblad Expeditions UK Ltd is acquiring 60% of White Desert Ltd (WDL Base Price $73.0M), 60% of PNR Airways Ltd (PNR Base Price $32.0M), and 42.86% of Echo Charlie Ltd (ECL Base Price $7.0M) from multiple sellers for an aggregate base consideration of approximately $112M, with completion payment adjusted for working capital, cash, indebtedness, and transaction costs. The buyer will also subscribe for additional ECL shares for $3.0M post-completion.

Laser Photonics closed a public offering on September 14, 2026, issuing 10,500,000 common shares plus dual warrant packages (10.5M Series B-1 and 10.5M Series B-2) at $0.75 per unit, raising gross proceeds of $7.9 million. All securities have an exercise price of $0.75; Series B-1 warrants expire in 5 years, Series B-2 in 24 months. H.C. Wainwright Co., LLC was the exclusive placement agent. Net proceeds will fund R&D, acquisitions, and working capital.

Forgent (NYSE: FPS) reported fiscal 2026 revenues of $1,420M (+89% YoY), net income of $106M (+508% YoY), and adjusted EBITDA of $323M (+91% YoY), all exceeding high-end guidance. Q4 FY2026 revenues reached $462M (+94% YoY) with record bookings of $1,503M (+375% YoY) and backlog of $3.0B (+256% YoY). The company announced a $35M incremental capacity expansion in Tijuana and initiated FY2027 guidance of $2,400–$2,600M revenues (+76% growth) and $575–$625M adjusted EBITDA (+86% growth).

Rocket Lab completed a $1.944 billion At-The-Market (ATM) equity offering, issuing 29.3 million shares, to secure cash consideration for its pending $1 billion+ acquisition of Iridium Communications. Simultaneously, Iridium amended its $1.775 billion term loan facility to permit the change of control and Rocket Lab terminated its $3.6 billion senior secured bridge facility, establishing permanent cost-effective financing backed by Iridium's free cash flow and a Rocket Lab parent guarantee. The Iridium acquisition is expected to close mid-2027, pending regulatory approvals.

Vera Therapeutics announced ORIGIN 3 final efficacy results for TRUTAKNA (atacicept-vymj) in IgA nephropathy: 428 patients showed placebo-adjusted eGFR stabilization of +5.6 mL/min/1.73m² at 52 weeks (p=0.0001) and 76% risk reduction in composite kidney disease progression (hazard ratio 0.24, p=0.0001). The company plans to submit a supplemental BLA in Q4 2026 for full FDA approval. Commercial momentum: 350+ patient start forms in first 10 weeks post-accelerated approval; cash position ~$499M plus $425M available via Oxford Facility.

Connect Biopharma announced positive topline results from a 160-patient Phase 2 study (Seabreeze STAT Asthma) of rademikibart for acute asthma exacerbations. The drug reduced treatment failure by 66% vs. placebo over 28 days (2.5% vs. 6.4% failure rate, p=0.153—not statistically significant due to lower-than-expected placebo failure rates) and showed statistically significant FEV1 improvement at Day 7 (250 mL vs. 120 mL, p=0.023). Safety was favorable; no new signals observed. Company plans to report Phase 2 COPD data later in September, then engage FDA on Phase 3 design.

Corteva's Board of Directors approved the previously announced separation of its seed business into Vylor Inc., a standalone publicly traded company. Shareholders of record as of September 24, 2026, will receive one Vylor share for each Corteva share held, via pro rata dividend on October 1, 2026 (tax-free to shareholders except fractional shares). Vylor will begin trading on NYSE under symbol VYLR; Corteva will continue as a pure-play agriculture company focused on crop protection and digital products.

Evommune disclosed Phase 2a proof-of-concept results for EVO301 (IL-18 binding protein) in moderate-to-severe atopic dermatitis (N=70): 34% placebo-adjusted EASI improvement at week 8 (33% at week 12); 23% achieved IGA 0/1 at week 12 versus 0% placebo; no treatment-related serious or severe adverse events. Company plans Phase 2b initiation mid-2027 with subcutaneous formulation. Additionally, EVO756 (MRGPRX2 antagonist) Phase 2b migraine trial initiated July 2026 with top-line data expected 2027, and EVO646 (TLR7/8 antagonist) Phase 1 planned 1H 2027. Cash position ~$287M with runway into 2029.

Summit presented updated June 2026 data from the Phase III HARMONi trial at WCLC 2026, showing ivonescimab plus chemotherapy achieved a hazard ratio of 0.76 (95% CI: 0.61–0.95; p=0.0151) for overall survival in the global population, with median OS of 16.8 months vs. 14.0 months for placebo (n=219 per arm). Western patients (n=83 ivonescimab, n=82 placebo) demonstrated consistent results with HR 0.76 (95% CI: 0.52–1.10) at median follow-up of 23.2 months. No new safety signals were observed. The FDA BLA has a PDUFA goal date of November 14, 2026.

AT&T announced an exclusive partnership where eligible wireless and fiber customers receive complimentary LifeMD virtual care and pharmacy memberships (normally $228/year/$19/month). Initially rolling out to 29 million customers in 11 states starting September 2026, expanding nationwide in January 2027. Customers pay only for individual visits ($29–$79) and prescriptions used, not the membership fee.

Jaguar Health executed multiple exchanges in September 2026: (1) Lincoln Alternative Strategies LLC exchanged a $175.0K convertible note for 557,377 common shares (9/11/26); (2) Streeterville Capital LLC exchanged preferred shares for 304,473 common shares across three transactions (7/7/26, 9/11/26, 9/14/26); (3) Joshua Mailman purchased 535,000 common shares and 2,077,255 pre-funded warrants for 284,653 shares of Napo Therapeutics (subsidiary holding) on 9/15/26. Total common shares issued: ~2,077,255 from warrant exercise potential plus ~861,850 from direct exchanges. All transactions utilized Section 3(a)(9) exemption; warrants exercisable at $0.0001/share starting 9/15/26.

On May 21, 2026, Spectral AI obtained FDA De Novo classification for its DeepView burn-wound healing prediction system, authorizing U.S. commercial sales. The company has secured a $150M BARDA contract with $86.6M committed to date, supporting deployment of 30 subsidized systems to U.S. burn/trauma centers. First commercial sales are targeted by year-end 2026. At June 30, 2026, the company held $14.0M cash against $14.9M notes payable and a $12.1M stockholders' deficit; H1 2026 revenue was $7.5M (down from $19.7M in FY2025 due to completion of development programs).

Harte Hanks announced expiration of its 60-day Go-Shop Period on September 15, 2026, during which the company solicited interest from 93 third parties and received unspecified Acquisition Proposals. The company designated Exempted Parties and reaffirmed its recommendation of the Star Equity Holdings merger agreement dated August 14, 2026, under which Star will acquire Harte Hanks for $5.00 cash or 0.50 shares of Star preferred stock per share, with aggregate cash capped at $19.2 million. The company faces a $1.152 million termination fee if it accepts a Superior Proposal post-Go-Shop; the Board has not yet determined any proposal qualifies as Superior.

Tessera issued 26,796 shares to Water IO Ltd. (CEO Menachem Shalom) on September 15, 2026, representing the maximum allowable issuance under NYSE American rules without stockholder approval from an original 800,000 share obligation. The remaining 53,205 shares (post-reverse split) require stockholder approval by June 30, 2027, or conversion to cash. Water IO has paid $500k of a $1M promissory note (original date April 10, 2026); $500k principal remains due under the amended note dated July 24, 2026.

Uranium Royalty Corp. completed its transformational Sweetwater acquisition in July 2026, funded partly by selling 593,255 lbs of U₃O₈ for $51.0M at $86.00/lb (vs. $85.45/lb market average). Q1 FY2027 net income jumped to $16.3M (from $1.0M YoY) on revenue of $51.0M with $34.1M cost of sales; diluted EPS rose to $0.10 (from $0.01). The deal positioned UROY as the largest U.S. non-precious metal royalty platform with 5.3M acres of land (largest in Wyoming, second-largest public U.S. landowner), with additional oil/gas upside from ~38,000 acres leased for exploration.

BiomX Inc. rebranded to Tessera Defense & Homeland Security Inc. on September 11, 2026, trading under NYSE American ticker HLSQ. The company raised over $4 million in the prior 3 months via at-the-market offering at ~$2.20/share (split-adjusted). It owns 100% of AI subsidiary Zorronet, 60% of detection-tech subsidiary DFSL, and 10% of M.E.A. Testing Systems (option to 78.9%). As of June 30, 2026, stockholders' equity was $10.9M ($17.6M total including $25.4M goodwill/intangibles from April acquisitions), above NYSE American listing standards. Company executed one-for-ten reverse stock split on September 9, reducing authorized shares to 150M.

Beta Bionics announced FDA clearance of Mint, a patch pump with reusable/disposable architecture launching Q1 2027, targeting 1.5M+ units in 2027. Simultaneously submitted 3D Intelligence (next-gen algorithm with three selectable experiences) to FDA via 510(k), expecting U.S. commercialization by end-2026 as iLet 3D and Q1 2027 as Mint 3D. Full-year 2026 revenue guidance lowered to $121–126M (from $131–136M) due to up to $10M Q4 deferral as users await Mint launch; 37–39% pharmacy reimbursement, 58.5–59.5% gross margin maintained.

Forward Industries (NASDAQ: FWDI, ~$3.3M market cap) announced a non-binding proposal on September 15, 2026 to acquire SkyAI Inc. at $2.13 per SkyAI share (50% premium to SkyAI's $1.42 closing price on September 14, 2026), via a fixed exchange ratio of 0.306 Forward shares per SkyAI share with a cash/stock election. The deal is contingent on due diligence, regulatory approval, SkyAI stockholder approval, and definitive agreement; Forward requested SkyAI Board response by September 25, 2026. No transaction size, SkyAI equity count, or SkyAI market cap disclosed in the filing.

On an unspecified date in 2026, USA Rare Earth (USAR) completed its merger with SVRE Holdings Ltd., issuing 126,849,307 shares of common stock (34.1% dilution to existing shareholders) to SVRE securityholders. USAR assumed SVRE's $465M+ DFC loan (bearing SOFR+4.0%, 15-year term, secured by first-priority liens on substantially all assets) and entered into an offtake agreement whereby US SIIE LLC purchases 100% of Phase I rare earth production from SVRE's Pela Ema mine in Brazil on a take-or-pay basis. The transaction subjects USAR to extensive restrictive covenants under the DFC finance agreement and offtake agreement, including restrictions on dividend payments, asset dispositions, and fundamental transactions, and grants the Counterparty a call option on SVRE's equity under specified triggering events.

On August 21, 2026, nVent Electric (via subsidiary Hoffman Schroff) agreed to acquire Maverick Power LLC, a data center power distribution manufacturer with ~900 employees and $527M TTM revenue (as of June 30, 2026), for $1.75B upfront plus up to $550M in performance-based consideration through 2028. nVent will finance the deal with ~$1.65B in new debt (net proceeds from notes offering plus $600M term loan and $250M revolving facility draw) and cash on hand, with a $1.5B bridge facility backstop. Closing expected Q4 2026.

Sabre Financial Borrower LLC (Sabre subsidiary) issued $1,350,000,000 of 9.875% Senior Secured Notes due 2032 (upsized from $1,100,000,000), priced September 15, 2026, closing expected September 28, 2026. Proceeds fund intercompany loan to Sabre GLBL, which will prepay existing intercompany debt and support tender offers. Concurrent tender offer by Sabre Financial targets $1,000,000,000 of 11.125% Senior Secured Notes due 2029 at $1,092.50 per $1,000 principal (early tender), plus consent solicitation to eliminate restrictive covenants and events of default. Sabre GLBL simultaneously launched tender offers for up to $250,000,000 of its own senior secured notes across three series (2029–2030 maturities) at prices ranging $975–$992.50 per $1,000. Legal counsel: Davis Polk Wardwell LLP (Sabre); Latham Watkins LLP (BofA Securities). Dealer manager: BofA Securities.

iPower Inc. issued a $3,000,000 Series A Senior Secured Convertible Note with a September 15, 2028 maturity date. The note converts at $3.156/share (150% of prior closing price for initial notes), accrues 10% annual interest payable in stock or cash, and includes multiple redemption rights upon events of default, changes of control, or asset sales. The note is secured by company collateral and includes extensive anti-dilution and conversion provisions.

Liberty Latin America is negotiating a complex financial restructuring involving ~$410M of new first-lien debt (6.50% coupon, 5-year tenor, backstopped by AHG), ~$1.15B of second-lien takeback debt at 8.00% from existing first-lien creditors, a 5-year $140M RCF extension at SOFR+400bps, and potential separation of its Puerto Rico telecom unit ("New LPR") via transition services agreement. Most recent term sheet dated September 11, 2026 shows SteerCo (creditor committee) and LLA continuing to negotiate equity allocation (creditors 100%, LLA receiving warrants for 5% equity with vesting tied to TSA completion or 5-year anniversary), governance, and operational separation terms. Key open items remain: exact leverage target (4.0x 2026E EBITDA = ~$1.56B total debt implied), warrant strike price, and TSA pricing grid.

AEye, Inc. (NASDAQ: LIDR) entered into an At Market Issuance Sales Agreement dated September 15, 2026 with A.G.P./Alliance Global Partners to sell up to $50,000,000 of common stock at-the-market. The agent will receive compensation of up to 3.0% of gross proceeds. The offering is registered on Form S-3 (File No. 333-296038) and may continue for up to 36 months or until all shares are sold. No specific dollar amount or share count has been drawn down yet; this is a framework agreement.

Al Shams Investments Limited (largest shareholder, holding 6,513,000 shares of BHR) announced September 14, 2026 its intention to nominate five independent candidates—Jennifer Bitterman, Jonathan Klein, Anna Massion, Sir Michael Peat, and Wayne Walker—for election to Braemar's Board at the November 13, 2026 Annual Meeting. Al Shams cites 90%+ stock-price decline since 2013 spin-off and sustained underperformance. The nominees possess substantial real estate, finance, and governance credentials. A joint filing and voting agreement binds all parties; Al Shams retains sole discretion over strategy and settlement terms.

NRx Pharmaceuticals received written notice from FDA's Office of Generic Drugs that its ANDA amendment for preservative-free ketamine (NRX-100) was reclassified from Major to Minor Amendment, eliminating the need for substantial FDA resource expenditure. The new GDUFA goal date is November 10, 2026. This reclassification accelerates the approval timeline for a drug addressing a stated shortage.

Hub Group amended its $450M revolving credit facility (Sept 11, 2026) extending financial statement delivery deadlines to Nov 30, 2026 and allowing add-back of 2026 restatement costs to EBITDA. Patrick O'Donnell appointed CFO (effective post-restatement filing); Todd Heeter extended as interim CFO through Apr 2027 with consulting fee increasing to $175K/month Dec 1 and $1.25M retention bonus upon 10-K filing. Company reported preliminary H1 2026 operating loss (pre-one-time charges), $1.7–$1.8B revenue guidance, and expects Nasdaq delisting notice but plans appeal.

Rocket Pharmaceuticals announced FDA alignment on its Phase 2 pivotal trial of RP-A501 for Danon disease. The FDA confirmed a 12-patient pivotal efficacy population (with first 3 already enrolled at recalibrated dose of 3.8×10^13 GC/kg), cleared continued enrollment under modified protocol with optimized immunomodulatory regimen, and established 12-month co-primary endpoints (myocardial LAMP2 protein expression and 10% reduction in left ventricular mass index) intended to support accelerated approval. Company expects to complete remaining 9 patient dosing by mid-2027.

BlossomHill Therapeutics reported Phase 1/2 SOLARA trial data for BH-30643, a novel EGFR inhibitor, showing 45% objective response rate (18/40 patients) and 88% disease control rate (35/40) in EGFR C797S-positive NSCLC patients resistant to prior EGFR inhibitors. The drug demonstrated favorable safety with low dose-reduction rates (9%) and discontinuation rates (3%) among 174 patients at expansion doses. BH-30643 recently received FDA Fast Track designation; the company plans to initiate a Phase 2 study in Q1 2027.

Cheetah Net Supply Chain Service Inc. (NASDAQ: CTNT) entered into a Membership Interest Purchase Agreement on September 15, 2026, to acquire 100% of JoyPak Supply LLC from Newland Asset Management LLC (65% owner) and Redwing Capital LLC (35% owner) for $788,000 total cash consideration: $88,000 initial payment within 2 business days of signing, and $700,000 closing payment within 2 business days after closing. Closing expected within 4 weeks, subject to due diligence completion. JoyPak operates in consumer, beauty, personal care, and everyday-use product sales.

Aethlon Medical amended executive employment agreements for James B. Frakes (CEO/CFO) and Steven P. LaRosa, MD (CMO) effective September 11, 2026. The amendments require all severance payments and COBRA health insurance continuation payments to be paid as single lump sums upon a change of control, rather than in installments, with health care payments fixed and non-reducible regardless of subsequent coverage. No dollar amounts or specific benefit calculations are disclosed in the filing.

Astrana Health raised its full-year 2026 Adjusted EBITDA guidance to $255–280M (midpoint $267.5M) from prior guidance, representing ~26% CAGR from FY2019. Q2 2026 delivered $972.5M revenue (+48.6% YoY) and $68.9M Adj. EBITDA. The company now operates across 16 markets with ~1.5M members in value-based care arrangements, 20,000+ providers, 81% of Q2 2026 capitation revenue from full-risk arrangements, and G&A improved 210 bps YoY to 5.6% of revenue through AI-native operating platform leverage.

10% owner NIPPON LIFE INSURANCE CO (CRBG) bought 171K shares (~$5.9M) on the open market (0.1% of holdings). Open-market insider purchase — historically a bullish signal.

Director DeSantis Damon (CELH) bought 36K shares (~$1.0M) on the open market (1.3% of holdings). Open-market insider purchase — historically a bullish signal.

GL Part SPV II, LLC (Wyoming LLC) filed a Schedule 13D on 2026-09-15 regarding acquisition of beneficial ownership in XCF Global, Inc. (public company, market cap ~$95.5M). The filing document itself does not disclose the specific percentage stake acquired, dollar amount, share count, or transaction date—only that a 13D filing was made, which typically indicates 5%+ beneficial ownership. Without access to the substantive Schedule 13D form content (only metadata provided), material deal terms cannot be specified.